- French mayor sorry for 'no one died' remark over mass rape trial
- Mohamed Al-Fayed, outsider shunned by British high society
- Lawyers say 'monster' late Harrods owner abused dozens of women
- India in box seat after Bumrah takes four against Bangladesh
- Taiwan retains death penalty but limits use to 'exceptional' cases
- Ferrari's Leclerc sets early pace in Singapore ahead of Norris
- 10 years into Huthi rule, some Yemenis count the cost
- France poised to finally get new govt
- Kompany, Alonso call for action on player workload amid strike talks
- Liverpool goalkeeper Alisson doubtful for Bournemouth clash
- Bumrah takes four as India bowl out Bangladesh for 149
- Sri Lanka 134-1 to take upper hand in first New Zealand Test
- Bayern's Kompany calls for game cap for players amid strike talks
- Christie's expands Hong Kong footprint in hope of art market 'pickup'
- Sultry screen legend Sophia Loren turns 90
- Cambodian opposition figure in court on incitement charge
- Bumrah takes three wickets to have Bangladesh in trouble at 112-8
- Kimchi threat as heatwave drives up South Korea cabbage prices
- UK economic data delivers fresh blow to new govt
- China to 'gradually resume' seafood imports from Japan after Fukushima ban
- India minister blames dam release for flooding
- O'Rourke strikes early for Kiwis as Sri Lanka trail by three
- Deep takes two as Bangladesh totter in reply to India's 376
- Israel pounds Lebanon's Hezbollah after device blasts
- Revolution or mirage? Controversy surrounds new Alzheimer's drugs
- Ashwin's 113 powers India to 376 in Bangladesh Test
- Biden opens home to 'Quad' leaders for farewell summit
- Sally Rooney returns with 30-something questions
- Wallabies sense 'massive' chance to upset All Blacks
- Taiwan questions two in probe into Hezbollah pagers
- Viral Korean Olympic shooter scores first acting role as assassin
- Farrell set for 'challenge' of downing Bordeaux in Top 14
- Springbok Etzebeth diverts attention from looming caps record
- Inter on a high ahead of Milan derby as Napoli face Juve test
- Bank of Japan leaves key interest rate unchanged
- Arnold quits after six years in charge of Australia
- Asian markets track Wall Street record to extend global rally
- Guirassy and Anton to return to Stuttgart with new side Dortmund
- Marseille bidding to continue 'almost perfect' Ligue 1 start
- Arnold quits as coach of Australia men's football team
- Harris and Oprah hold star-studded US election rally
- Allies to remember failed WWII parachute operation
- Perez leading new-look Villarreal charge against leaders Barca
- Man City face Arsenal in Premier League title showdown, Postecoglou under pressure
- Fake celebrity endorsements, snubs plague US presidential race
- Documentary brings Argentine 'death flights' to the big screen
- Strike shows challenge to Boeing 'reset' of labor relations
- World leaders to gather at UN as crises grow and conflicts rage
- How plastic pollution poses challenge for Canada marine conservation
- Scientists track plastic waste in pristine Canada marine park
'Beginning of the end': patients hail new treatment for drug-resistant TB
Volodymyr is celebrating a major milestone on Wednesday -- it's his final day of taking a new treatment hailed as a turning point in the fight against drug-resistant tuberculosis.
The 25-year-old doctor in Ukraine's capital Kyiv said he had nasty neurological side effects when he was on a previous drug regimen, which takes up to two years, involves a huge number of pills and is less than 60-percent effective.
But the new treatment course took just six months, and gave him very few side effects. "It was very easy," he told AFP.
A scan on Wednesday showed he was clear of tuberculosis, and he plans to start work next week after eight months off sick.
"Now I can start life again," said Volodymyr, who did not give his last name.
Tuberculosis, once called consumption, was the world's biggest infectious killer before the arrival of Covid-19, with 1.5 million people dying from the disease each year.
Around five percent of new cases are resistant to commonly prescribed antibiotics, making them difficult to treat.
However a new drug regimen, called BPaL because it combines the antibiotics bedaquiline, pretomanid and linezolid, has been seen as a breakthrough since it was first approved by the US Food and Drug Administration in 2019.
- From 23 to five pills a day -
Research in 2020 showed that the BPaL regimen cured more than 90 percent of drug-resistant patients, however there was a high rate of side effects linked to linezolid, including nerve pain and bone marrow suppression.
But a study published in the New England Journal of Medicine on Wednesday indicated that the dosage of linezolid can be halved.
A trial involving 181 participants with drug-resistant tuberculosis was carried out in Russia, South Africa, Georgia and Moldova -- all countries with high TB rates.
It found that while 1,200 milligrams of linezolid over six months had a cure rate of 93 percent, that number only dropped to 91 percent if the dosage was halved to 600 milligrams.
The number of participants with the side of peripheral neuropathy -- which causes nerve pain -- fell from 38 to 24 percent at the lower dosage, while the rate of bone marrow suppression dropped from 22 to two percent.
The study's lead author, Francesca Conradie of South Africa's University of the Witwatersrand, said she was "overwhelmed with how successful this regimen was".
"This is the beginning of the end of drug-resistant TB," she told AFP.
"The quicker you treat someone's TB, the less infectious they are -- it's like Covid in many ways."
It is also far easier for patients to take BPaL, she added, saying previous courses could involve 23 pills a day -- and up to 14,000 total pills over the maximum two-year course.
BPaL involves five pills a day -- and fewer than 750 over six months.
- Could TB surpass Covid? -
Nataliia Lytvynenko, who has overseen BPaL treatments in Ukraine, said the more manageable amount of pills meant it was easier for patients to continue treatment after being displaced by the war in her country.
The World Health Organization indicated earlier this year that it would soon update its guidelines to recommend most patients with drug-resistant TB use BPaL with 600 milligrams of linezolid.
Two experts not involved in Wednesday's study said the research and the WHO guidance were "major advances".
The BPaL treatment "is one of the defining achievements of the tuberculosis research community in this century," Guy Thwaites of Britain's Oxford University and Nguyen Viet Nhung of Vietnam's National Tuberculosis Control Programme wrote in an editorial in the New England Journal of Medicine.
The advances come amid warnings that the pandemic has stalled progress against tuberculosis.
"I very much worry that TB will -- whether it's this year or next -- again become the largest single killer of any infectious disease in the world," said Mel Spigelman, the president of the non-profit TB Alliance which funded the research.
Volodymyr meanwhile said he hoped that progress would continue so the treatment timeline gets even shorter.
"Maybe it will be two months -- or even one," he said with a smile.
A.Malone--AMWN